Lowey Dannenberg P.C. is investigating ADMA Biologics for potential violations of federal securities laws. The investigation follows a March 24, 2026 report by Culper Research alleging that ADMA Biologics engaged in channel stuffing by inducing a distributor to stock excess ASCENIV through rebates and extended payment terms, which allowed the company to report 20% revenue growth in 2025 instead of an actual 3% decline. Attorney Andrea Farah stated the probe concerns whether the company and its executives provided accurate and complete information to investors. Investors who suffered losses exceeding $50,000 in ADMA Biologics securities are encouraged to contact the firm.
ADMA Biologics IncInvestigation into alleged channel stuffing and securities law violations following short-seller report.